Brace Pharma

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 21
Average round size
info
The average size of a deal this fund participated in
$44M
Portfolio companies 15
Rounds per year 2.62
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.43
Exits 6
Key employees 2
Stages of investment
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
Summary

Brace Pharma is the famous VC, which was founded in 2013. The venture was found in North America in United States. The leading representative office of defined VC is situated in the Rockville.

Speaking about the real fund results, this VC is 11 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 investment rounds annually. The increased amount of exits for fund were in 2018. Opposing the other organizations, this Brace Pharma works on 2 percentage points more the average amount of lead investments. Deals in the range of 10 - 50 millions dollars are the general things for fund.

We also calculated 2 valuable employees in our database.

Among the most popular portfolio startups of the fund, we may highlight F2G, Antiva Biosciences, Navitor Pharmaceuticals. The fund has specific favorite in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Genetics, Health Diagnostics. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the Brace Pharma, startups are often financed by Atlas Venture, Amgen Ventures, Remeditex Ventures. The meaningful sponsors for the fund in investment in the same round are Atlas Venture, Sectoral Asset Management, Remeditex Ventures. In the next rounds fund is usually obtained by Perceptive Advisors, Logos Capital, Square 1 Bank.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Brace Pharma:
Typical Co-investors
Brace Pharma is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Brace Pharma:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Turnstone Biologics

Biotechnology
Innovation Management
Therapeutics
$80M14 Jul 2021 San Francisco, California, United States

Pipeline Therapeutics

Pharmaceutical
$80M11 Feb 2021 San Diego, California, United States

ReViral

Biotechnology
Health Care
Medical
Therapeutics
$44M25 Aug 2020 England

F2G

Biotechnology
Genetics
Health Care
Medical
Pharmaceutical
$60M12 Aug 2020 Manchester, England, United Kingdom

HotSpot Therapeutics

Biopharma
Biotechnology
Health Care
Life Science
Pharmaceutical
Therapeutics
$65M21 May 2020 Cambridge, Massachusetts, United States

Pipeline Therapeutics

Pharmaceutical
$32M18 Dec 2019 San Diego, California, United States

Avidity Biosciences

Biotechnology
Life Science
Pharmaceutical
$100M13 Nov 2019 San Diego, California, United States

Avidity Biosciences

Biotechnology
Life Science
Pharmaceutical
$16M17 Oct 2018 San Diego, California, United States

ReViral

Biotechnology
Health Care
Medical
Therapeutics
$55M01 Aug 2018 United Kingdom, England, United Kingdom
News
Turnstone Biologics Raises $80 Million Series D Financing

– Turnstone Biologics Corp. announced the successful completion of an $80m Series D financing co-led by PFM Health Sciences and Point72.
– New investors include Eventide Asset Management, Surveyor Capital (a Citadel company), Ridgeback Capital Investments, Takeda Ventures, CaaS Capital, JM Family Enterprises, Inc., Northleaf Capital Partners, 404 Bio and an undisclosed investor.
– The round was joined by existing investors Versant Ventures, OrbiMed, F-Prime Capital, Sectoral Asset Management, Sixty Degree Capital, Brace Pharma Capital and Teralys Capital.
– Proceeds from the financing will be used to advance Turnstone’s pipeline of programs from its oncolytic virus and TIL therapy platforms.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Brace Pharma?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: